- Founded
- 2021-01-01 in India
- Headquarters
- India
Zenex Animal Health is India’s second‑largest animal health company, formed in July 2021 when a consortium led by Multiples Private Equity acquired the animal health business of Cadila Healthcare Limited (now Zydus Lifesciences). Headquartered in India, the company is dedicated to improving livestock productivity and farmer livelihoods through science‑driven veterinary solutions. Its product portfolio spans farm‑care products, feed supplements, vaccines, dewormers, and therapeutic treatments primarily for cattle, buffalo, and poultry. Zenex also emphasizes antimicrobial resistance (AMR) mitigation, partnering with organizations such as the Asian Development Bank to train farmers and veterinarians in antibiotic stewardship. In February 2026, the company announced the acquisition of a majority stake in Netherlands‑based VievePharm, expanding its European footprint. Zenex has raised over $62 million from investors including the Asian Development Bank, International Finance Corporation (IFC), CPP Investments, and Multiples Alternate Asset Management. The company was reportedly exploring a stake sale or IPO at a valuation exceeding $1 billion as of 2025. With a strong R&D focus and a commitment to biosecurity and animal welfare, Zenex is a key player in the rapidly growing Indian animal health market.
Detailed Review
History and Formation
Zenex Animal Health was established in 2021 through a carve‑out from Cadila Healthcare’s animal health division, funded by Multiples Private Equity and later joined by co‑investors including the Asian Development Bank (ADB). The company inherited a diversified product line that includes vaccines, feed supplements, anti‑infectives, dewormers, and herbal preparations. Its primary customers are smallholder dairy and poultry farmers across India, Bangladesh, Nepal, and Sri Lanka.
Strategic Focus
The company’s strategic focus is on reducing livestock disease risk and improving farm productivity. In December 2021, ADB invested up to $10 million in Zenex, coupled with a $575,000 technical assistance grant to train 2,300 farmers and 580 veterinarians on antimicrobial resistance (AMR) management. This initiative aims to promote responsible antibiotic use and alternative biosecurity practices, with at least 40% of participants being women.
Growth and Expansion
Zenex has also pursued inorganic growth. In February 2026, it acquired a majority stake in VievePharm, a Netherlands‑based animal health company, signaling its ambition to enter European markets. Financially, the company has raised approximately $62.5 million from global institutional investors. According to a 2025 report by Mint, the company’s owners were exploring a sale or IPO that could value the business at over $1 billion.
Operations and R&D
The company operates through a network of distributors and a direct sales force focused on veterinary clinics, dairy cooperatives, and poultry integrators. Its R&D efforts concentrate on developing new vaccine strains and antibiotic alternatives. Despite being relatively young, Zenex has established itself as a major competitor to multinationals and domestic players in the Indian animal health sector.
Challenges and Outlook
Challenges include regulatory hurdles in new markets, competition from established players like Boehringer Ingelheim and Zoetis, and the need to continuously address AMR concerns. Nevertheless, its strong investor backing, acquisition strategy, and focus on sustainability position it for continued growth.
Key Products
Vaccines & Therapeutics
A range of vaccines and therapeutic drugs such as dewormers and anti-infectives for cattle, buffalo, and poultry.
Feed Supplements
Nutritional additives designed to improve livestock health, growth, and productivity.
Farm-Care Products
Disinfectants and biosecurity solutions for farm hygiene and disease prevention.
Companion Animal Products
Expanding line of herbal and conventional health products for pets, including dogs and cats.
Vaccines
Preventive vaccines for cattle, buffalo, and poultry against common diseases.
Therapeutic Products
Anti‑infectives, anti‑inflammatory drugs, and dewormers for treatment.
Herbal & Alternative Products
Natural remedies and probiotic formulations aimed at reducing antibiotic use.
Offices & Headcount
1626 employees (approx.)